ReviewFuture oncology (London, England)2025
Patritumab deruxtecan in breast cancer treatment: a drug evaluation.
Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Roles of Her3 in carcinogenesis and advances in Her3-targeted cancer therapy.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a complex disease due to its heterogeneity. While there have been impressive advancements in the treatment of the different breast cancer subtypes, challenges persist when the tumor develops acquired treatment resistance and finally progresses on a given therapy. Since human epidermal growth factor receptor 3 (HER3) plays a key role in developing resistance to several anticancer therapies, many efforts have been performed over the last decades to effectively target HER3. However, most of these attempts have been unsuccessful due to their limited efficacy or severe toxicity. Numerous antibody-drug conjugates (ADCs) targeting HER3 are now being explored. Patritumab deruxtecan (U3-1402; HER3-DXd), the most advanced ADC targeting HER3 in clinical development, has demonstrated significant antitumor activity and a manageable safety profile in patients with breast cancer. This efficacy has been observed across diverse tumor subtypes and varying levels of HER3 expression. In this review, we will analyze the results of clinical trials investigating HER3-DXd in breast cancer and explore its potential role in future clinical applications and treatment algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.